arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Alpha Teknova, Inc.

TKNO
$7.89 ▲ +0.52 (+7.06%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
7 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Alpha Teknova, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $422.0M
Dividend Yield —
Revenue Growth 7.4% ↗
Op. Margin -41.9% ↗
ROIC -20.8% ↗
FCF / Share $-0.18 ↗
Trailing P/E —
Price / Book 6.1x
FCF Yield —
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.52M
↑ +7.4% —
Net Income Profit after all expenses
$-17.26M
↑ +35.5% —
Operating Margin Operating profit as % of sales
-41.9%
↑ +39.5% 6th
FCF / Share Free cash flow per share
$-0.18
↑ +36.7% —
Long-Term Debt Long-term obligations
$13.12M
↑ +39.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
7
Returns ↓
25
Financial Health ↑
51
Cash Quality ↓
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters